Skip to content

Study · Case report or series · n = 1 · 2026

1 result

Refractory Chronic Kidney Disease-Associated Pruritus: Old Remedies and Novel Agents.

Li KC, Smyth B, Brown M, Asif M, Brennan F

Kidney medicine11 Mar 2026

PMID42027200 (opens in a new tab)PMCIDPMC13099442 (opens in a new tab)DOI10.1016/j.xkme.2026.101315 (opens in a new tab)PepBankPUB-42027200
Download PDFPubMedAsk about this study
Jump to 1 result

Summary

Refractory chronic kidney disease associated pruritus (CKDaP) has limited therapeutic options, leading to significant distress, profound sleep disturbance, and reduced quality of life. We describe 2 cases of severe CKDaP in which conventional treatments were unsuccessful and novel therapeutic strategies were employed. The first case involves a patient receiving hemodialysis who achieved significant symptom relief with a subcutaneous lignocaine infusion, delivered using a syringe driver over 2 weeks followed by oral mexiletine. The second case concerns a kidney failure patient managed on the conservative kidney management pathway, who experienced marked improvement following weekly intravenous difelikefalin despite not receiving chronic hemodialysis. These cases underscore the challenges faced by patients and clinicians in managing severe CKDaP and its profound impact on quality of life and emotional distress. Furthermore, these cases highlight the variability in individual treatment responses and the therapeutic potential of repurposed medicines and emphasize the need for further research in this area.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In a kidney failure patient receiving conservative management without chronic haemodialysis, weekly intravenous difelikefalin markedly improved pruritus.

    In plain wordsIn a kidney failure patient without chronic haemodialysis, weekly intravenous difelikefalin markedly improved itching.

    Peptide
    Difelikefalin
    Outcome
    DecreasePruritus improvement
    Study

    n = 1

    Outcome group
    Skin and hair · Skin and wound
    Studied dose
    Dose not stated · intravenousAs given in this study (human).

    Source sentences

    Summary
    The second case concerns a kidney failure patient managed on the conservative kidney management pathway, who experienced marked improvement following weekly intravenous difelikefalin despite not receiving chronic hemodialysis.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.